How to Add a New Randomized Part to an Ongoing Study in Three Weeks

Case Study

 
Home / Clinical Technologies /

One of the world’s leading biotechnology companies was focusing on area of highly unmet medical need and developing a pipeline of medicines with breakaway potential to treat some of the toughest cancers.

The Sponsor had a longstanding relationship with Almac Clinical Technologies spanning more than two decades and when they learned from a regulatory agency that they would need to add a new part to the trial, they reached out for Almac’s support on how best to proceed.

This posed a question, when reconfiguring the existing IRT could delay the study for many weeks, could building a new IRT actually be quicker?

In this case study, read about Almac’s approach to rapidly accommodating protocol design configurations and data integration.

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies